• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Tasso & InnoVero to Supply Anti-Doping Test to 2024 Paris Olympics, Expanded Partnership

by Syed Hamza Sohail 07/10/2024 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know:

– InnoVero, a global leader in providing innovative, athlete-centric collection technologies to anti-doping organizations worldwide and Tasso, Inc., the leading provider of patient-centric, clinical grade blood collection solutions, today announced the extension of their partnership that was first initiated in 2021.

– In addition to collaboratively developing new athlete-centric solutions, InnoVero will continue to serve as the exclusive worldwide distributor of Tasso blood collection solutions for the anti-doping marketplace.

Revolutionizing Anti-Doping: InnoVero and Tasso’s SAFESystem™ for Secure, Painless Blood Testing

As part of the InnoVero SAFESystem™ product suite, a secure, intuitive, and virtually painless system for anti-doping blood testing has been co-developed. This system leverages Tasso’s signature capillary blood collection technology, eliminating the need for traditional venipuncture or fingerstick collections. This innovative solution has been well-received by athletes, doping control officers, administrators, and laboratories, and is increasingly utilized in anti-doping programs worldwide. Professional and Olympic sports organizations, including those for the upcoming Paris 2024 Olympic Games, have quickly adopted this athlete-centric technology.

InnoVero delivers innovation and integrity to the global anti-doping community with solutions that secure global athlete trust. The SAFESystem™ sample collection solutions, featuring advanced security mechanisms, ensure that sample collection bottles are secure, athlete-friendly, and tamper-evident. These features provide seamless and efficient use for athletes, doping control officers, and laboratories, serving clients globally.

“Our partnership with Tasso is helping us deliver on our promise to drive innovation and integrity in anti-doping products. Tasso’s signature capillary blood collection technology has significantly improved the blood collection process providing an efficient, easy-to-implement, and athletic-centric solution” said Gabe Baida, Executive Director of InnoVero. “The response to our Tasso-based collection system from athletes and anti-doping organizations has been very positive. We are pleased to extend our partnership with Tasso and excited to continue developing innovative solutions together at the forefront of anti-doping technology.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Virta Health CEO: GLP-1s Didn’t Kill Weight Watchers, Its Broken Model Did

Most-Read

Lessons Learned from The Change Healthcare Cyberattack, One Year Later

Lessons Learned from The Change Healthcare Cyberattack, One Year Later

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Omada Health Launches "Nutritional Intelligence" with AI Agent OmadaSpark

Omada Health Soars in NASDAQ Debut, Signaling Digital Health IPO Rebound

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |